Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (1274)	3/11/2002 5:15:40 PM
From: nigel bates	Read Replies (1) \| Respond to of 1475

Protein Design Labs Begins Phase II Trial of Nuvion(TM) In Steroid-Refractory Graft-Versus-Host Disease Message 17183283 ...PDL previously reported results from a Phase I study of Nuvion in steroid-resistant GvHD in which patients received either seven low daily doses of Nuvion or a single higher dose. The results indicated that doses of up to 3.0 mg/m2 were well tolerated, and that Nuvion achieved a partial and complete response rate of 100%. In the group of 12 patients receiving a single dose at 3.0 mg/m2, seven patients had a complete response and all seven are alive with a median survival of more than one year...